Gilead Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio
Gilead Sciences (Foster City, CA): 34 reconciled FDA prescription therapies, $10.92B 2024 CMS Part D & Medicaid spend, and 70 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Foster City, CA |
| Reconciled FDA Portfolio Therapies | 34 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2031-01-01 |
| 2024 CMS Total Public Spend | $10.92B |
| 2024 Medicare Part D Spend | $6.18B |
| 2024 Medicaid Spend | $4.73B |
| California HCAI SB 17 Filings | 70 WAC filings (max 26.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.